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Abstract
The human FBN1 gene encodes fibrillin-1 (FBN1); the main component of the 10–12 nm
diameter extracellular matrix microfibrils. Marfan syndrome (MFS) is a common inherited
connective tissue disorder, caused by FBN1 mutations. It features a wide spectrum of dis-
ease severity, from mild cases to the lethal neonatal form (nMFS), that is yet to be explained
at the molecular level. Mutations associated with nMFS generally affect a region of FBN1
between domains TB3-cbEGF18—the "neonatal region". To gain insight into the process of
fibril assembly and increase our understanding of the mechanisms determining disease
severity in MFS, we compared the secretion and assembly properties of FBN1 variants con-
taining nMFS-associated substitutions with variants associated with milder, classical MFS
(cMFS). In the majority of cases, both nMFS- and cMFS-associated neonatal region vari-
ants were secreted at levels comparable to wild type. Microfibril incorporation by the nMFS
variants was greatly reduced or absent compared to the cMFS forms, however, suggesting
that nMFS substitutions disrupt a previously undefined site of microfibril assembly. Addi-
tional analysis of a domain deletion variant caused by exon skipping also indicates that reg-
ister in the neonatal region is likely to be critical for assembly. These data demonstrate for
the first time new requirements for microfibril biogenesis and identify at least two distinct
molecular mechanisms associated with disease substitutions in the TB3-cbEGF18 region;
incorporation of mutant FBN1 into microfibrils changing their integral properties (cMFS) or
the blocking of wild type FBN1 assembly by mutant molecules that prevents late-stage lat-
eral assembly (nMFS).
Introduction
Fibrillins are large (~350 kDa) multifunctional glycoproteins that constitute the major struc-
tural component of the 10–12 nm diameter microfibrils of the extracellular matrix (ECM) in
metazoan species [1]. In addition to providing a scaffold for the deposition of elastin during
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elastic fibre synthesis in higher vertebrates, microfibrils play a role in tissue homeostasis and
development through their interactions with growth factors such as transforming growth fac-
tor β (TGFβ) and the bone morphogenetic proteins (BMP). They also influence cell-matrix
communication via interactions with the integrins α8β1, αvβ1, αvβ5, αvβ3, αvβ6, αIIbβ3 and α5β1
[2–7]. In humans, three fibrillin isoforms, FBN1, -2 and -3, are expressed from separate genes
[8–12]. The majority of mutations affecting FBN1 result in Marfan syndrome (MFS); one of
the most common human connective tissue disorders affecting the cardiovascular, skeletal and
ocular systems.
A characteristic feature of diseases caused by mutations in FBN1 is their marked phenotypic
variability, with differences in disease severity being seen even between members of a single
family carrying the same disease allele in cases of MFS [13]. Few clear genotype-phenotype
correlations have been established except in cases of rare diseases caused by mutations in spe-
cific FBN1 domains. Stiff skin syndrome, for example, is caused by mutations affecting domain
TB4 [14] while the dominant forms of geleophysic dysplasia and acromicric dysplasia are
linked to substitutions in domain TB5 [15]. In both of these cases, the mutant proteins secrete
and incorporate into matrix [16]. In contrast, mutations affecting domains TB4 and TB5 that
lead to intracellular retention of the mutant protein cause MFS [16], consistent with a func-
tional haploinsufficiency mechanism in these cases. Genotype-phenotype correlations that
explain MFS severity are rarer although an exception is neonatal MFS (nMFS), which is linked
to a cluster of mutations affecting domains TB3-cbEGF18 of FBN1; the "neonatal region".
Cases of nMFS are atypically severe, presenting with symptoms of MFS at birth, and are gener-
ally lethal in infancy. At present, little is known about the molecular mechanisms underlying
nMFS although previous work has shown that FBN1 nMFS variants show altered protease sus-
ceptibilities and a reduced affinity for heparin [17].
When viewed by rotary shadowing, isolated fibrillin microfibrils have a beaded filament
appearance with an average untensioned periodicity of 50–60 nm [18–20]. The domain orga-
nisation of the fibrillins has been highly conserved throughout evolution [21–23], being domi-
nated by 43 calcium-binding epidermal growth factor-like (cbEGF) domains interspersed with
7 transforming growth factor β-binding protein-like (TB) domains (Fig 1A). Although the
organisation of fibrillin monomers within the microfibrils is still a matter of controversy [24,
25], a variety of molecular and cellular data have suggested a model of microfibril assembly
dependent on pericellular proteolysis, heparan sulphate interactions and regulated multimeri-
sation. At the point of secretion, or immediately afterwards, fibrillin is processed by furin,
which removes a C-terminal propeptide that regulates assembly [26, 27]. The exposed C-ter-
minal domains then associate into bead-like structures [28], enhancing the apparent affinity of
the region for the N-terminal domains of other fibrillin molecules and promoting the head-to-
tail alignment of the polypeptides. Throughout the process, avidity-driven interactions with
cell surface heparan sulphate proteoglycans limit the diffusion of the nascent microfibrils
[29–31].
To investigate the pathogenic mechanisms leading to the wide spectrum of disease severity
seen in MFS, we compared the fibroblast secretion profiles of a series of FBN1 mini-gene con-
structs harbouring nMFS or cMFS mutations within the neonatal region. The secretion pro-
files of full-length, GFP-tagged FBN1 nMFS and cMFS variants were then compared using a
HEK293T-based transient transfection assay. In most cases, the mutant proteins secreted at
levels similar to wild type. When assessing the incorporation of the GFP-tagged FBN1 variants
into the ECM through co-cultures with fibroblasts, however, clear differences were seen
between the two classes with incorporation of the nMFS mutants being greatly reduced or
absent compared to the cMFS forms. Our results provide further evidence of a dominant nega-
tive mechanism in cases of cMFS involving cbEGF domain substitutions and show that nMFS
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results from the disruption of a microfibril assembly site (or sites) within domains TB3-
cbEGF18, with mutant molecules likely blocking the late-stage assembly of wild-type FBN1.
These data also show that the length and Ca2+-dependent structure of the TB3-cbEGF18
region are both critical for native assembly of the 10–12 nm microfibril.
Materials and methods
Plasmid construction, mutagenesis and transfection
Construction of the plasmid pcDNA-GFPFBN has been described previously [26]. Plasmids
for the expression of the NterPro-TB3cbEGF19 constructs were created by amplifying the
DNA encompassing encoding residues D952 to T1403 as a SalI fragment from a FBN1 cDNA
clone and inserting this into the XhoI site of the plasmid pKG52(polyA) [32], which encodes
the N-terminal region of FBN1 up to the proline-rich domain (residues 1–446) under the
Fig 1. FBN1 domain organisation and sites of neonatal Marfan syndrome mutations. A) The structure of FBN1 is
dominated by cbEGF domains interspersed with TB domains. The majority of nMFS-associated mutations affect the
central TB3- cbEGF18 domains, which have traditionally been referred to as the "neonatal region". B) A model of the
neonatal region (i) was created using Modeller software [35] and coordinates from the structures of domains TB4 [4],
cbEGF12-13 [36] and cbEGF32-33 [37]. TB3 is coloured blue, cbEGFs are coloured green with Ca2+ ions shown as
grey spheres. Substitutions associated with cMFS (panel ii, orange) are found evenly distributed across the neonatal
region while those associated with nMFS (panel iii, red) show a clustering around cbEGF11-12. C) Plotting the
positions of known nMFS-associated substitutions on a schematic representation of a cbEGF domain shows that in
many cases the effect of the substitution is structural, affecting either cysteines involved in disulphide bond formation
(yellow) or Ca2+-binding consensus residues (red). Where nMFS and cMFS substitutions have been found at the same
position, the cMFS version is shown in brackets. Data extracted from the Universal Mutation Database (http://umd.be/
FBN1) [38].
https://doi.org/10.1371/journal.pone.0248532.g001
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control of a thymidine kinase promoter. Mutant constructs were created by overlap extension
PCR [33].
For the transfection of MSU-1.1 fibroblasts, 2.5 μg of plasmid DNA was mixed with 5 μl
TranIT-X2 transfection reagent (Mirus) in 250 μl OPTIMEM reduced serum medium and
incubated at room temperature for 20 minutes. DNA complexes were then added to cells at
~95% confluence in a well of a 6-well tissue culture dish with 2.5 ml Dulbecco’s modified Eagle
medium supplemented with 2 mM glutamine, 50 U/ml penicillin, 50 μg/ml streptomycin and
10% (v/v) fetal bovine serum (complete DMEM). After 24 hours, cells were harvested with
trypsin and transferred to 75 cm2 tissue culture flasks. Selection was commenced 4 days after
transfection with 2.5 μg/ml puromycin in complete DMEM, with medium changes every 2–3
days for 3 weeks. Pooling of clones (typically >80 clones per pool) was used to average out the
effects of variations in expression levels between individual clones resulting from random
genomic integration and to overcome the low transient transfection efficiency of fibroblasts.
Transfections of HEK293T cells with GFP-FBN1 constructs were carried out in 6-well
plates using 3 μl of TransIT-X2 transfection combined with 500 ng DNA in 100 μl OPTIMEM
reduced serum medium. After 20 minutes incubation, transfection complexes were added to
cells in 2.5 ml complete DMEM and incubated overnight before harvesting for either secretion
or microfibril incorporation assays.
Microfibril incorporation assay
Microfibril incorporation assays were carried out as described previously [16, 26] with some
modifications. Briefly, HEK293T cells were transfected in 6-well plates overnight then trypsi-
nised and counted. Co-cultures on 13 mm diameter glass coverslips were established using 2 x
105 FS2 dermal fibroblasts [14] and 2 x 105 transfected HEK293T cells per well of 24 well
plates. Cells were cultured in complete DMEM for five days then fixed with 4% (w/v) parafor-
maldehyde in phosphate-buffered saline and stained using a rabbit polyclonal antibody raised
against the FBN1 proline-rich region [32] and chicken polyclonal anti-GFP (Abcam; ab13970)
without permeabilisation. Goat anti-chicken Alexa488 and goat anti-rabbit Alexa568 (Invitro-
gen) were used for detection. Images were collected using a Zeiss Axioplan 2 microscope with
AxioVision Rel. 4.8 software.
Immunoblotting
Cells remaining from the HEK293T transfections were transferred to 25 cm2 tissue culture
flasks (Greiner) and grown for a further 3 days in complete DMEM to produce cell and
medium samples for analysis by Western blotting. Conditioned media and cell samples were
analysed by immunoblotting as described previously [32, 34] using a chicken anti-GFP anti-
body followed by a goat anti-chicken HRP conjugate and enhanced chemiluminescent detec-
tion (Amersham).
Results
Neonatal MFS sites are unevenly distributed across FBN1 domains
TB3-cbEGF18
FBN1 domains TB3-cbEGF18 (Fig 1A) have traditionally been referred to as the "neonatal
region" since the vast majority of mutations identified in cases of nMFS cluster in these
domains. To gain an insight into the different molecular mechanisms underlying nMFS and
cMFS, we used the Universal Mutation Database entry for FBN1 (http://www.umd.be/FBN1/)
to map the positions of known nMFS-associated mutations within FBN1 (Fig 1B; S1 Table). As
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expected, the majority of nMFS-associated mutations affected domains TB3-cbEGF18. Muta-
tions affecting regions outside this area are rarer and include 1 bp or 2 bp deletions leading to
frameshifts (c.390delT and c.7167_7168delCT), deletions in the cDNA spanning multiple
domains (c.2294_2854del, c.5423_5788del and c.5546_5917del corresponding to ΔcbEGF8-10,
ΔcbEGF26-28 and ΔcbEGF27-29, respectively), splice variants (c.IVS35-32del20a) and substi-
tutions (C129Y, I817M, C2181F, C2489R). Interestingly, the distribution of nMFS-associated
substitutions within domains TB3-cbEGF18 is uneven, with half of the mutations affecting
only domains cbEGF11 and cbEGF12 (Fig 1B). In contrast, cMFS-associated substitutions
within domains TB3-cbEGF18 (S2 Table) are more evenly distributed, suggesting that muta-
tions affecting domains cbEGF11 and cbEGF12 are particularly likely to result in nMFS. Addi-
tionally, there are cases in which different substitutions at the same amino acid position lead to
either cMFS or nMFS (Fig 1C), suggesting that both position and residue type are important
in determining disease severity.
Looking more closely at the types of nMFS-associated substitutions that occur in cbEGF
domains, most (33/38) are predicted to have structural consequences that would alter the fold
of the domain, affecting residues involved in either calcium-binding or disulphide bond for-
mation (Fig 1C). Of the cysteine substitutions, the majority reported in the UMD (20/22) affect
either the Cys1-Cys3 or Cys5-Cys6 disulphide, with only two affecting the Cys2-Cys4 disul-
phide (C1081G and C1053R). Of the remaining five substitutions, I1048T has previously been
reported to introduce an N-linked glycosylation site [39] and also affects a predicted site of
interdomain packing between domains TB3 and cbEGF11 [33]. Both of these effects would
have structural consequences. The remaining four substitutions (I817M, K1043R, A1337P,
K1381N) are not obviously structural, but could indicate patches involved in intermolecular
interactions.
Secretion from fibroblasts of MFS-associated FBN1 neonatal region
mutants
To compare the effects of substitutions causing nMFS or cMFS on FBN1 secretion from fibro-
blasts, we used a previously described assay [32, 34] in which pools of stably transfected clones
of the human fibroblast cell line, MSU-1.1, are created to express a FBN1 mini-gene construct
(Fig 2A). MSU-1.1 fibroblasts are able to assemble extracellular microfibrils and express all the
cellular factors required for FBN1 folding, processing and secretion [40]. For this assay, the
mini-gene construct encodes the N-terminal domains of FBN1 up to the proline-rich region
fused to domains TB3-cbEGF19, spanning the entire neonatal region. The proline-rich region
provides an epitope for the detection of the fusion construct (MW ~130 kDa) by immunoblot-
ting. Five substitutions (I1048T, E1073K, C1086Y, C1111R, N1131Y) [41–48] and a domain
deletion resulting from a splice site mutation (ΔcbEGF16) [49, 50] linked to nMFS were gener-
ated for comparison with a series of substitutions associated with milder disease (Fig 2B);
either cMFS (Y1101C, D1113G, D1115G, N1382S) or isolated aortic aneurysm and dissection
(G1127S) [42, 44, 49, 51–56].
In many cases, both nMFS and cMFS constructs were found to secrete from fibroblasts (Fig
2B). This was unexpected for the N1131Y, D1113G and D1115G variants in cbEGF13, which
in a previous study were shown to be retained in cells [34]. The I1048T variant migrated at a
higher molecular weight compared to the wild-type construct, consistent with the introduction
by this substitution of an additional N-linked glycosylation site [39]. The ΔcbEGF16 deletion
construct migrated more rapidly as expected due to the loss of domain cbEGF16. Its presence
in the medium indicates that any structural changes to the molecule resulting from the new
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interdomain packing interaction between domains cbEGF15 and cbEGF17 do not block
secretion.
nMFS and cMFS mutants differ in their capacity to incorporate into
microfibrils
To assess the ability of nMFS and cMFS variants to incorporate into microfibrils in the context
of a full-length FBN1 molecule, we used a microfibril incorporation assay [26] in which
HEK293T cells, transiently transfected with wild-type or mutant versions of GFP-tagged FBN1
(GFP-FBN1), are co-cultured with human dermal fibroblasts. Human dermal fibroblasts are
difficult to transfect and the production of stably transfected lines expressing a construct of the
size of full-length FBN1 (coding sequence of 8.6 kb) is extremely inefficient. Transient trans-
fection of HEK293T cells in this assay overcomes these difficulties. HEK293T cells transfect
with high efficiency, but are unable to assemble a microfibril network, so the ability of tagged
mutant molecules to assemble in co-cultures with fibroblasts can be assessed clearly.
Fig 2. Construction of the NterPro-TB3cbEGF19 mini-gene and secretion of cMFS and nMFS variants from
fibroblasts. A) NterPro-TB3cbEGF19 is a fusion of the N-terminal domains of FBN1 up to the proline-rich region
(orange) with domains TB3 to cbEGF19, which encompass the neonatal region. Western blotting using an antibody
directed against the proline-rich domain (orange) is used to distinguish the fusion construct from endogenous FBN1
expressed by fibroblasts on the basis of size. B) Model of the TB3-cbEGF19 domains highlighting the positions of the
nMFS (red spheres) and cMFS (orange spheres) substitutions described in this work, and the position of domain
cbEGF16, which is deleted in one of the nMFS variants. Domain TB3 is coloured blue, cbEGF domains are coloured
green and Ca2+ ions bound to the cbEGF domains are shown as grey spheres. C) Secretion profiles of the neonatal
region mutants associated with nMFS and cMFS. Medium samples from untransfected MSU-1.1 fibroblasts (MSU-1.1)
and fibroblasts transfected with the wild-type (WT) construct were used as controls to allow the identification of the
recombinant construct (MW ~130kDa, arrowed). Full-length FBN1, expressed endogenously by the fibroblasts,
functions as a loading control (MW ~350kDa, arrowed).
https://doi.org/10.1371/journal.pone.0248532.g002
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When expressed in HEK293T, full-length GFP-FBN1 fusion constructs behaved similarly
to the mini-gene constructs used to assess secretion from fibroblasts. In most cases, the GFP
fusions were detected on western blots of medium samples prepared from transiently trans-
fected HEK293T cultures (Fig 3). The secretion of the nMFS-associated C1086Y variant was
found to be greatly reduced compared to wild-type GFP-FBN1 although it was still detectable
on western blots, in contrast to previously studied cysteine—to—tyrosine substitutions affect-
ing FBN1 domains TB4 and TB5 [16]. Similarly, the nMFS-associated C1111R variant showed
reduced but readily detectable levels of secretion from HEK293T compared to wild-type
GFP-FBN1. Little difference was observed in the apparent migration of the I1048T and
ΔcbEGF16 constructs compared to wild-type in these experiments, in contrast to the fibroblast
secretion data, as a result of the high molecular weight of the GFP-FBN1 fusion and the low
resolving power of SDS-PAGE in this size range.
To assess the incorporation of the nMFS and cMFS mutants into microfibrils, co-cultures
of FS2 human dermal fibroblasts and transiently transfected HEK293T cells were grown for 5
days at confluence, fixed and stained for GFP and FBN1 without permeabilisation (Figs 4 and
5). Omitting a permeabilisation step makes it possible to distinguish between the GFP-reactive
material outside cells and the GFP-fusion inside the HEK293T cells, which will not be stained
by the anti-FBN1 antibody and appears as green "spots" in the merged immunofluorescence
images. When co-cultured with FS2 fibroblasts, clear differences were seen in the behaviour of
the GFP-FBN1 constructs harbouring nMFS versus cMFS mutations. Very little or no evidence
Fig 3. Secretion of full length GFP-FBN1 fusion constructs from HEK293T cells. Mutations associated with nMFS
(neonatal) or cMFS (classical) were engineered into GFP-tagged FBN1 cDNA construct and transiently transfected
into HEK293T cells. After 3 days of culture, samples of cells and medium fraction were analysed by Western blotting
with an antibody directed against the GFP epitope. Empty vector (pcDNA) and wild-type construct (GFP-FBN1) were
used as negative and positive controls. The majority of mutant constructs were easily detected in the culture medium.
The C1086Y variant was consistently seen at reduced levels in the medium compared to the other constructs. Cell
fraction samples indicated that expression levels were similar across the different variants and that the reduction seen
for the C1086Y variant was not due to a lack of expression. �The G1127S substitution, which was identified in cases of
isolated aortic aneurysm rather than cMFS, is associated with a milder form of disease and so is grouped with the
cMFS variants here.
https://doi.org/10.1371/journal.pone.0248532.g003
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of microfibril incorporation of the GFP fusion was seen in co-cultures of the nMFS mutants,
in spite of their secretion from the HEK293T cells (Fig 4). Only rarely were fine strands of
GFP-reactive material observed to co-localise with FBN1 (not shown). In contrast, the cMFS
variants and the G1127S variant associated with an isolated aortic disease phenotype were
Fig 4. Microfibril incorporation of GFP-FBN1 nMFS variants. FS2 fibroblasts were co-cultured for 5 days with
HEK293T cells transiently transfected to express GFP-FBN1 (WT) or variants associated with nMFS. Co-cultures were
then fixed and stained with anti-GFP and anti-FBN1 antibodies without permeabilisation [16, 26]. Although the nMFS
variants I1048T, E1073K, C1111R, N1131Y and ΔcbEGF16 were clearly detectable in medium samples when expressed
as GFP-FBN1 fusions, microfibril networks labelled with the recombinant GFP-FBN1 (arrow in WT panel) were rarely
seen. Bar = 100 μm.
https://doi.org/10.1371/journal.pone.0248532.g004
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easily detectable although the staining for these constructs in the matrix often appeared weaker
than for wild-type GFP-FBN1 (Fig 5). These results show for the first time that the nMFS and
cMFS mutants can be separated into two distinct classes based on their ability to incorporate
into microfibrils using this assay, with the nMFS variants appearing to disrupt a motif(s) in
FBN1 required for its incorporation into microfibrils.
Discussion
The work presented here compares the molecular and cellular fates of FBN1 variants within
the TB3-cbEGF18 region associated with classical and severe “neonatal” forms of MFS to
gain an insight into the mechanisms that determine disease severity. Fundamental to the
Fig 5. Microfibril incorporation of GFP-FBN1 cMFS variants. FS2 fibroblasts were co-cultured for 5 days with
HEK293T cells transiently transfected to express GFP-FBN1 (WT) or variants associated with cMFS. Co-cultures were
then fixed and stained with anti-GFP and anti-FBN1 antibodies without permeabilisation [16, 26]. In contrast to the
nMFS variants, co-cultures expressing GFP-cMFS variants produced microfibril networks containing readily
detectable recombinant material (white arrows). Bar = 100 μm.
https://doi.org/10.1371/journal.pone.0248532.g005
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development of MFS is the reduction in quantity and/or quality of FBN1-containing microfi-
brils in the ECM. FBN1 null alleles resulting from genomic deletions of the FBN1 gene [57]
have been reported and demonstrate the importance of haploinsufficiency in MFS pathogene-
sis. Early studies on the mgR and mgΔ mouse models also indicated that a critical threshold of
microfibrils was necessary for the maintenance of elastic tissues such as the aorta [58, 59].
However, no satisfactory explanation for the difference in severity of disease in MFS has been
forthcoming. Our results, utilising a microfibril incorporation assay with GFP-FBN1 disease-
causing variants, together with fibroblast secretion analysis, now provide new evidence for two
different mechanisms of microfibril dysfunction underlying cMFS and nMFS. Most variants
analysed were secreted into the media of co-cultures, and showed no evidence of degradation,
but only cMFS FBN1 variants incorporated readily into microfibrils. The nMFS variants, in
contrast, appear to be blocked from incorporating into microfibrils, strongly suggesting the
presence of a previously undefined assembly site within domains TB3-cbEGF18.
Our data suggest a plausible model, based on two different mechanisms, to explain the
development of cMFS and nMFS associated with substitutions in the TB3-cbEGF18 region. In
the milder cMFS form, mutant FBN1 molecules are able to assemble with wild type, or close to
wild type, efficiency into microfibrils, as all necessary sites of assembly are present and func-
tional. Although there may be differences in the incorporation efficiencies of the cMFS vari-
ants, this may not be detectable using the current assay system given its semi-quantitative
nature. Incorporation of the cMFS-associated substitution C1663R in cbEGF24 [49, 60] has
previously been reported in a transgenic mouse model [61]. Loss of microfibril function in
these cases may develop gradually as a result of differences in the biomechanical properties of
the mutant microfibrils compared to wild type, or susceptibility to degradation. In contrast,
the nMFS mutants show greatly reduced or no incorporation into microfibrils indicating dis-
ruption of a previously unrecognised assembly site. In cases of nMFS, mutant and wild type
molecules would be able to associate in the early assembly stages since they have native N-and
C-termini capable of multimerisation (Fig 6A), however the nascent microfibrils would be
blocked from further assembly due to defective heparin- or protein-protein interactions
involving the neonatal region. This interaction would result in non-productive complexes (Fig
6B) that effectively reduce the pool of assembly-competent FBN1 to levels lower than those
that would be expected for haploinsufficiency, leading to the more severe phenotype observed
in nMFS.
Of the disease-causing substitutions investigated here, almost all affect domains cbEGF11-
13 and are predicted to cause structural changes through effects on Ca2+ binding (E1073K,
D1113G, D1115G, N1131Y and N1328S), disulphide bond formation (C1086Y and C1111R),
disruption of an interdomain packing site (I1048T and Y1101C), altered glycosylation
(I1048T) or deletion of an entire domain (ΔcbEGF16). The majority were processed and
secreted from cells at levels comparable to wild type. Surprisingly, only a subset including
Y1101C (cbEGF12), D1113G, D1115G, and G1127S (cbEGF13), and N1382S (cbEGF19),
incorporated into microfibrils, whilst I1048T (cbEGF11), E1073K, C1086Y, and C1111R
(cbEGF12), N1131Y (cbEGF13), and ΔcbEGF16 did not. These data indicate that the structural
changes have a different impact on assembly, which is not simply explained by levels of secre-
tion. The exceptions to this may be C1086Y and C1111R, which showed a reduced level in the
extracellular medium compared with other variants. The variable consequences for assembly
and disease severity shown by the cbEGF13 calcium-binding substitutions D1113G, D1115G
(cMFS) and N1131Y (nMFS) suggest a more significant functional role for N1131. This could
be due to the degree of structural perturbation caused by loss of calcium binding to cbEGF13
and/or additional roles for the central β-hairpin on which residue N1131 is located. In EGF12
of the Notch receptor, residues on the central β-hairpin contribute to a specific binding
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platform for ligand, and contain additional post-translational modifications involved in pro-
tein recognition [62]. Thus, although all disease-causing variants with single amino acid substi-
tutions studied here are predicted to have structural effects, only those associated with nMFS
disrupt an interaction site sufficient to stall later stages of assembly.
In a previous study of cbEGF domain substitutions associated with nMFS and cMFS [34],
using a mini-gene construct encoding FBN1 domains cbEGF11-22 and the same fibroblast
secretion assay described here, the three calcium-binding site variants D1113G, D1115G and
N1131Y variants all failed to secrete. The fold of domain cbEGF12 in this context was found to
be dependent on Ca2+ binding by cbEGF13, suggesting a post-translational rather than co-
translational model of folding in this region, since cbEGF13 would be translated after
cbEGF12. In addition, data from limited proteolysis experiments exposed long-range, N-ter-
minally directed effects, with the fold of cbEGF11 being influenced by substitutions in
Fig 6. Model of the FBN1 neonatal region’s roles in microfibril assembly and nMFS pathogenesis. A) In normal
FBN1 assembly, secretion of the protein is coupled to the proteolytic cleavage (1) of the C-terminal propeptide (red
circle). FBN1 interactions with heparan sulphate proteoglycans (HS), at sites including the N- and C-termini and
neonatal region (other sites not shown), limit diffusion from the cell surface during assembly. Multimerisation of C-
terminal domains, previously blocked by the propeptide, initiate the assembly process (2) and promote intermolecular
avidity-driven interactions with N-terminal domains (3) that result in a head-to-tail alignment of monomers. The
neonatal region (green) may be involved in the higher order, lateral assembly of FBN1 to form the mature microfibril
(4). B) Lateral assembly (panel A, step 4) would occur between FBN1 molecules (black and grey) that have already
undergone C-terminal multimerisation and head-to-tail alignment. Compared to the wild type case (i), cMFS-
associated mutations in the neonatal region (ii; orange) appear to incorporate into microfibrils at near-normal levels.
In contrast, mutations affecting the neonatal region that lead to nMFS (iii; red) are unlikely to affect N- to C-terminal
interactions but would disrupt later stages of assembly such as lateral association. Mutants such as ΔcbEGF16 may not
directly affect the neonatal assembly site, but would affect the position and register of the region in the maturing
microfibril. In addition to preventing the incorporation of mutant molecules into microfibrils, the interaction between
wild type and mutant variants at step 3 would reduce the amount of wild type FBN1 deposited into the matrix,
resulting in microfibril levels that are less than expected for haploinsufficiency.
https://doi.org/10.1371/journal.pone.0248532.g006
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cbEGF13. Interactions with N-terminal domains, especially in the context of TB-cbEGF pairs,
where extensive hydrophobic interfaces can be formed [4, 33], are known to stabilise the Ca2+
binding site and therefore the fold of cbEGF domains [63]. Our new data, showing secretion
of the D1113G, D1115G and N1131Y variants in the context of both the NPro-TB3cbEGF19
fusion and full-length GFP-FBN1 constructs, suggest that domain TB3 plays a stabilising role
in the fold of domains cbEGF11-13 and highlight the importance of assessing, where possible,
the effects of substitutions in the context of a full-length molecule. Through its interdomain
interactions with cbEGF11, domain TB3 could indirectly influence the fold of cbEGF12 and
may act as an intramolecular chaperone to mitigate the disruptive effects of substitutions in
cbEGF13, at least to the extent that they are not detected by cell surveillance methods.
What interactions might drive higher order assembly beyond the initial C-terminal multi-
merisation step? In a previous comparison of nMFS and cMFS mutants [17], FBN1 fragments
harbouring nMFS substitutions were shown to have a reduced affinity for heparin compared
to cMFS variants, which bound at levels similar to wild-type. The fragments used in that study,
spanning from EGF4-cbEGF22, contain the entire neonatal region with just a single one of the
seven known FBN1 heparin-binding sites, localised to cbEGF12-14 [64]. These data indicate
that the surface properties of the EGF4 to cbEGF22 region are sufficiently altered in nMFS, but
not cMFS, FBN1 variants, to affect a heparin interaction, although do not exclude a disrupted
protein-protein interaction. Furthermore, our study of the ΔcbEGF16 nMFS variant shows
that it is not only the cbEGF11-13 region that is critical for higher order assembly. The lack of
microfibril incorporation associated with this variant indicates there are also spatial con-
straints on assembly in this region, since the cbEGF11-13 region is intact.
Given that 8 molecules of fibrillin are predicted to form the fibrillar structure (based on
STEM mass mapping [18] and TEM imaging [65]) and the interbead region comprises near
linear Ca2+-stabilised sections, it is likely that a number of lateral interactions as well as N- to
C-terminal interactions, are required to guide higher order assembly. This would explain the
requirement for site-specific and length constraints. It is interesting that high resolution struc-
tural analysis of an EGF domain-rich Notch receptor/ligand complex indicates a number of
primary and secondary interaction sites along a longitudinal axis, which define the orientation
of the ligand relative to the receptor [66]. It is possible that fibrillin monomers are arranged in
a similar way within the microfibril, with multiple interaction sites contributing to macromo-
lecular architecture.
The involvement of the neonatal region in microfibril assembly has important implications
for models of microfibril organisation. Currently, two main models exist to explain the
arrangement of fibrillin monomers within microfibrils: a “pleated” model in which each fibril-
lin molecule spans a single interbead distance [24, 67] and a staggered model in which each
monomer stretches over two interbead distances [25, 33, 37, 68]. Both models involve a head-
to-tail alignment of monomers, however the staggered arrangement is dependent on at least
one additional lateral association occurring to generate the observed 56 nm periodicity and
would be consistent with our proposed model for the role of the neonatal region in assembly.
Although the neonatal region is not currently known to interact with other FBN1 domains, it
may be that earlier assembly steps (e.g., head-to-tail alignment of monomers) are required
before an interaction with the neonatal region can take place, either by increasing the avidity
of an interaction or through the creation of a new interacting surface.
Previously, using a similar assay, we demonstrated MFS-associated substitutions in
domains TB4 and TB5 of FBN1 resulted in intracellular retention of the mutant molecules
[16] whilst apparently similar mutations associated with SSS, acromicric dysplasia and geleo-
physic dysplasia secreted normally. In these cases, the MFS phenotype was caused by disrup-
tion of the globular structure (with a core consisting of an aromatic residue surrounded by a
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conserved tetrad of salt-bridges [4, 69]), which was sufficient to result in cellular retention of
the mutant form and a haploinsufficiency mechanism. SSS, acromicric dysplasia and geleophy-
sic dysplasia variants in contrast did not alter the incorporation into microfibrils, suggesting
that the disease arises due to a specific disruption of TB4/TB5 implicated in integrin-mediated
signalling.
In this study we have shown that the cMFS variants are able to incorporate into 10–12 nm
microfibrils in cooperation with WT protein, but the microfibril formed is likely to be some-
what defective in structure and function. In contrast, the nMFS variants are unable to assemble
to form 10–12 nm microfibrils but would still be expected to have the capacity to multimerise
via C-terminal sequences and form complexes with WT protein and thus create non-produc-
tive multimers. Since a threshold level of fibrillin has been shown to be important for manifes-
tations associated with MFS, it is plausible to explain the severe effects of nMFS by a
substantial reduction of microfibrils below the haploinsufficiency level, caused by a dominant
negative effect. For the cMFS variants studied by this assay, we can observe incorporation of
the mutant form, but we cannot exclude effects on the efficiency of assembly. Indeed, it would
be unlikely for there to be no impact of structural mutations occurring at a key interaction site.
Therefore, there may also be quantitative effects on assembly, as well as defective properties of
microfibrils themselves.
Subtle details explaining the spectrum of milder cases of MFS are still to be determined.
The R2726W substitution has been reported in several cases of mild MFS with isolated skeletal
symptoms [70–72]. In COS-1 cells, this substitution reduces, but does not abolish, cleavage of
the C-terminal propeptide [73], suggesting that FBN1 levels in these cases are higher than the
threshold required for a complete MFS phenotype, and that a kinetic defect underlies mild dis-
ease. Allelic variation in the expression level of the wild-type allele has also been linked to
intrafamilial differences in severity, with higher expression levels of the wild-type protein
being associated with milder disease [13]. This effect of increased wild-type expression was
clearly shown using the Fbn1C1039G/+ mouse model, where introduction of a wild type human
FBN1 transgene rescued the aortic phenotype associated with the C1039G/+ background [61].
Conclusions
This cellular study has, for the first time, distinguished differences in the ability of nMFS and
cMFS variants in the TB3-cbEGF18 region of FBN1 to assemble into 10–12 nm microfibrils.
Despite all the variants having structural effects on the pairwise interactions and fold of the
cbEGF domains, only those associated with nMFS failed to incorporate into microfibrils. We
therefore propose that nMFS arises predominantly as a consequence of dominant negative
effects of mutant variants on assembly, leading to a gross reduction in microfibril quantity.
cMFS by contrast either arises by a haploinsufficiency mechanism or by dominant negative
effects that do not substantially affect assembly, but interfere with the integral properties of
microfibrils.
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